Avalo Therapeutics Executives Sell Shares, Buy Others Amid Market Volatility
ByAinvest
Friday, Apr 3, 2026 3:20 pm ET1min read
AVTX--
Avalo Therapeutics, Inc. (AVTX) has disclosed several transactions involving its top executives. On April 1, 2026, Chief Medical Officer Doyle Mittie sold 679 shares at $16 per share and subsequently purchased 679 shares at $8.04 per share. Additionally, Chief Financial Officer Sullivan Christopher Ryan sold 500 shares at $15.86 per share, as well as 7,479 shares at $16.83 per share and 6,200 shares at $17.02 per share on the same day. On April 2, 2026, Ryan also sold 1,780 shares at $17.57 per share. These transactions are subject to regulatory scrutiny and may be of interest to investors and analysts following the company's performance.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue



Comments
No comments yet